CLINICAL TRIAL: TWO DOSES OF GW433908/RITONAVIR GIVEN WITH ABACAVIR/LAMIVUDINE C

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是：1)了解服用福沙普那韦加100 mg RTV加ABC/3TC FDC是否与服用福沙普那韦加200 mg RTV加ABC/3TC FDC一样有效；2)测量T细胞；3)收集两种治疗方法的安全性信息；4)评估脂肪营养不良综合征的体征和症状；5)测量特定时间点的阿普利那韦的血药浓度，以确定是否正确用药。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purposes of this study are: 1) to find out if taking fosamprenavir with 100 mg RTV plus ABC/3TC FDC is as effective as taking fosamprenavir with 200 mg RTV plus ABC/3TC FDC; 2) to measure T-cells; 3) to collect information on the safety of the two treatments; 4) to assess the physical signs and symptoms of lipodystrophy syndrome; 5) to measure the amounts of amprenavir in blood at certain time points to find out if medication has been taken correctly.